The randomised, phase 3 IMvigor010 study did not meet its primary endpoint of disease-free survival (DFS) after treatment with adjuvant atezolizumab in patients with muscle-invasive urothelial cancer. Overall survival (OS) follow-up is ongoing. Additional exploratory biomarkers and subgroup analyses may warrant further study.
Radical surgery with or without cisplatin-based neoadjuvant chemotherapy is the current standard-of-care for muscle-invasive urothelial carcinoma. However, there is no conclusive level I evidence for adjuvant chemotherapy value with regard to OS, and only up to 50% of patients are eligible for cisplatin-based chemotherapy. Atezolizumab, an anti-PD-L1 antibody, is indicated as monotherapy in multiple locally advanced or metastatic urothelial carcinoma disease settings.
The IMvigor010 study evaluated the benefit of adjuvant atezolizumab versus observation in patients with high-risk muscle-invasive urothelial carcinoma of the blad...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Novel drug for kidney cancers/VHL patients Next Article
First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.